,Investigator On
0,"Dalbavancin as an Option for Treatment of S. aureus Bacteremia (DOTS): A Phase 2b, Multicenter, Randomized, Open-Label, Assessor-Blinded Superiority Study to Compare the Efficacy and Safety of Dalbavancin to Standard of Care Antibiotic Therapy for the Completion of Treatment of Patients with Complicated S. aureus Bacteremia  awarded by  Duke University"
1,Private Grant  awarded by  SCYNEXIS
2,Private Grant  awarded by  MAYNE PHARMA INC
3,Private Grant  awarded by  SUMMIT OXFORD LIMITED
4,"Private Grant  awarded by  CIDARA THERAPEUTICS, INC. - NEW"
5,Private Grant  awarded by  CONTRAFECT CORPORATION
6,Private Grant  awarded by  AMPLYX PHARMACEUTICALS INC
7,The Natural History of Antifungal Failure in Invasive Candidiasis in the United States  awarded by  UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER (HOUSTON)
